| Mary E Bukovitz, MD | |
|
1817 W Morris Blvd, Morristown, TN 37813-2837 | |
| (423) 581-3904 | |
| (423) 581-6120 |
| Full Name | Mary E Bukovitz |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 1817 W Morris Blvd, Morristown, Tennessee |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164517942 | NPI | - | NPPES |
| 3149630 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 6021 (Tennessee) | Primary |
| Entity Name | Summit Medical Group, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659090298 PECOS PAC ID: 2860396330 Enrollment ID: O20031125000793 |
News Archive
PrECOG, LLC is reporting clinical efficacy and biomarker analyses from its single-arm phase two study PrE0505 for the initial treatment of patients with malignant pleural mesothelioma.
A new study published on the bioRxiv* preprint aimed to identify highly immunoprevalent CD8 T-cell epitopes specific to SARS-CoV-2 that are confirmed to be endogenously processed and presented on frequently expressed HLA alleles.
Roche has announced that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease (CKD).
Researchers at Juntendo University report in the journal Leukemia how mutants of the protein calreticulin lead to molecular mechanisms triggering myeloproliferative neoplasms, which can cause cancer. The findings may lead to the development of novel therapies for certain types of blood cancer.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mary E Bukovitz, MD 1225 E Weisgarber Rd Ste 200, Knoxville, TN 37909-2675 Ph: (865) 584-4747 | Mary E Bukovitz, MD 1817 W Morris Blvd, Morristown, TN 37813-2837 Ph: (423) 581-3904 |
News Archive
PrECOG, LLC is reporting clinical efficacy and biomarker analyses from its single-arm phase two study PrE0505 for the initial treatment of patients with malignant pleural mesothelioma.
A new study published on the bioRxiv* preprint aimed to identify highly immunoprevalent CD8 T-cell epitopes specific to SARS-CoV-2 that are confirmed to be endogenously processed and presented on frequently expressed HLA alleles.
Roche has announced that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease (CKD).
Researchers at Juntendo University report in the journal Leukemia how mutants of the protein calreticulin lead to molecular mechanisms triggering myeloproliferative neoplasms, which can cause cancer. The findings may lead to the development of novel therapies for certain types of blood cancer.
› Verified 5 days ago
Renee A Salansky, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 1817 W Morris Blvd, Morristown, TN 37813 Phone: 423-581-3904 Fax: 423-581-6120 | |
Dr. Larry Michael Toffoletto, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1817 W Morris Blvd, Morristown, TN 37813 Phone: 423-581-3904 | |
John W Wilkinson, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1817 W Morris Blvd, Morristown, TN 37813 Phone: 423-581-3904 Fax: 423-581-6120 | |
Eric G Delay, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 420 W Morris Blvd, Ste. 400g, Morristown, TN 37813 Phone: 423-581-2538 Fax: 423-581-2660 | |
David V Willbanks, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1817 W Morris Blvd, Morristown, TN 37813 Phone: 423-581-3904 Fax: 423-581-6120 | |
R Alan Jamison, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1817 W Morris Blvd, Morristown, TN 37813 Phone: 423-581-3904 Fax: 423-581-6120 |